SG11201807336RA - Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof - Google Patents

Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof

Info

Publication number
SG11201807336RA
SG11201807336RA SG11201807336RA SG11201807336RA SG11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
antibodies
california
march
Prior art date
Application number
SG11201807336RA
Inventor
James D Marks
Daryl Drummond
Melissa Geddie
Dmitri Kirpotin
Neeraj Kohli
Alexey Lugovsky
Original Assignee
Univ California
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Merrimack Pharmaceuticals Inc filed Critical Univ California
Publication of SG11201807336RA publication Critical patent/SG11201807336RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111 01110111100101110111110 111110111011# 11 International Bureau 0.. .... .. ..... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/160775 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: FRANCIS, Carol L.; Bozicevic, Field & Francis A61K 39/395 (2006.01) C07K 16/46 (2006.01) LLP, 201 Redwood Shores Pkwy., Suite 200, Redwood C07K 16/18 (2006.01) City, California 94065 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/022188 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 13 March 2017 (13.03.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (30) Priority Data: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/309,365 16 March 2016 (16.03.2016) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/309,383 16 March 2016 (16.03.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/309,374 16 March 2016 (16.03.2016) US ZA, ZM, ZW. (71) Applicants: THE REGENTS OF THE UNIVERSITY (84) Designated States (unless otherwise indicated, for every OF CALIFORNIA [US/US]; 1111 Franklin Street, kind of regional protection available): ARIPO (BW, GH, Twelfth Floor, Oakland, California 94607 (US). MER- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, RIMACK PHARMACEUTICALS, INC. [US/US]; One TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Kendall Square, Building 700, Suite B7201, Cambridge, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Massachusetts 02139 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, — LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, _ (72) Inventors: MARKS, James D.; 107 Ardmore Road, Kens- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ington, California 94707 (US). DRUMMOND, Daryl; 1 GW, KM, ML, MR, NE, SN, TD, TG). = Brooks Road, Lincoln, Massachusetts 01773 (US). GED- DIE, Melissa; 28 Brand Street, Arlington, Massachusetts Published: 02474 (US). KIRPOTIN, Dmitri; 382 Ocean Avenue, — with international search report (Art. 21(3)) Apt. 1509, Revere, Massachusetts 02151 (US). KOHLI, before the expiration of the time limit for amending the Neeraj; 7 Wheaton Road, Arlington, Massachusetts 02474 claims and to be republished in the event of receipt of (US). LUGOVSKY, Alexey; 35 Audrey Road, Belmont, amendments (Rule 48.2(h)) = — Massachusetts 02478 (US). = — with sequence listing part of description (Rule 5.2(a)) = = = (54) Title: PROTEIN A BINDING POLYPEPTIDES, = 80— = 2 _ ce _ a = E 60 '2 — 2, 40— _ co fo 3 11 15 20— kin -E IN . IN © % / / /, / / ,,, • a .„.•,. ANTI-EPHA2 ANTIBODIES iii , 0 r ( / /,;.. 7 ., AND METHODS OF USE THEREOF VH: TS1 F5 F5 TS1 A7 A7 TS1 F5 A7 1-1 FIG. 1 VL: TS1 A7 TS1 TS1 TS1 F5 A7 F5 A7 IN 1-1 (57) : Provided by the present disclosure are antibodies (e.g., scFvs) that include CDRs and human framework regions that 0 confer useful properties upon the antibodies. In certain embodiments, such properties include thermostability (e.g., increased melting \" temperature), efficient binding to Staphylococcus aureus Protein A, or both. In certain aspects, the antibodies are internalizing anti - 0 bodies that specifically bind to the tumor associated antigen EphA2.
SG11201807336RA 2016-03-16 2017-03-13 Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof SG11201807336RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662309365P 2016-03-16 2016-03-16
US201662309374P 2016-03-16 2016-03-16
US201662309383P 2016-03-16 2016-03-16
PCT/US2017/022188 WO2017160775A1 (en) 2016-03-16 2017-03-13 Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201807336RA true SG11201807336RA (en) 2018-09-27

Family

ID=59852234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807336RA SG11201807336RA (en) 2016-03-16 2017-03-13 Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof

Country Status (12)

Country Link
US (1) US20170267768A1 (en)
EP (1) EP3429624A4 (en)
JP (1) JP2019515645A (en)
KR (1) KR20180127344A (en)
CN (1) CN108778328A (en)
AU (1) AU2017234275A1 (en)
BR (1) BR112018015898A2 (en)
CA (1) CA3016676A1 (en)
MX (1) MX2018009389A (en)
SG (1) SG11201807336RA (en)
TW (1) TW201738275A (en)
WO (1) WO2017160775A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California Anti-tumor antigen antibodies and methods of use
CN109467593A (en) * 2018-11-30 2019-03-15 北京泽勤生物医药有限公司 Application of the extracellular fragment of low pH insertion peptide as antigen
CN114437205A (en) * 2020-11-05 2022-05-06 多玛医药科技(苏州)有限公司 Anti-coronavirus antibody and application thereof
WO2022250431A1 (en) 2021-05-25 2022-12-01 주식회사 박셀바이오 Monobody-based chimeric antigen receptor and immune cell including same
CN113651889B (en) * 2021-07-16 2023-06-02 西南医科大学 anti-EphA 2 fully human bivalent recombinant antibody scFv-Fc
KR20230022810A (en) * 2021-08-06 2023-02-16 한국생명공학연구원 Novel Anti-EphA2 Chimeric Antigen Receptor and Immune Cell Expressing the Same
CN113980138B (en) * 2021-08-11 2023-08-11 卡瑞济(北京)生命科技有限公司 EphA2 chimeric antigen receptor and uses thereof
WO2023196869A1 (en) * 2022-04-05 2023-10-12 Atreca, Inc. Epha2 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
PT2352763E (en) * 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
US20130022604A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California Anti-tumor antigen antibodies and methods of use
US20130310281A1 (en) * 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
KR101632620B1 (en) * 2011-07-27 2016-06-23 글락소 그룹 리미티드 Anti-vegf single variable domains fused to fc domains
EP2716298A1 (en) * 2012-10-03 2014-04-09 Institut Pasteur A nod2-dependant pathway of cytoprotection of stem cells
BR112018068000A2 (en) * 2016-03-16 2019-02-05 Merrimack Pharmaceuticals Inc docetaxel generation nanoliposome compositions targeting the ephrin a2 receptor (epha2)

Also Published As

Publication number Publication date
AU2017234275A1 (en) 2018-10-04
EP3429624A4 (en) 2020-04-22
US20170267768A1 (en) 2017-09-21
KR20180127344A (en) 2018-11-28
MX2018009389A (en) 2018-11-21
CA3016676A1 (en) 2017-09-21
JP2019515645A (en) 2019-06-13
TW201738275A (en) 2017-11-01
WO2017160775A1 (en) 2017-09-21
BR112018015898A2 (en) 2019-01-22
CN108778328A (en) 2018-11-09
EP3429624A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
SG11201807336RA (en) Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810883TA (en) Combination therapy
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201810640RA (en) Cd33 specific chimeric antigen receptors
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof